Skip to content [s] Site map [3] Home [1]
Graphic text
Button

Cancer Research and Foundation News

Drug approved for HER2+ Breast Cancer

June 11, 2012

On June 8, 2012, the U. S. Food and Drug Administration approved pertuzumab injection (PERJETA) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

FDA explores change in breast cancer drug approval

June 5, 2012

Regulators are moving the goal posts in testing new drugs for breast cancer in the hopes of giving more women with aggressive, early-stage cancers the chance to try breakthrough drugs while they have the best shot at a cure.

Pap & HPV testing - cervical cancer screening facts

May 30, 2012

Cervical cancer screening, which includes the Pap test and HPV testing, is an essential part of a woman’s routine health care because it can detect cancer or abnormalities that may lead to cancer of the cervix.


Share this Page

Stay Connected

Button Button Button Button

Get Hope!

Sign up for our newsletter and updates.

CHRISTUS Stehlin Foundation for Cancer Research

10301 Stella Link Road, Suite A
Houston, Texas 77025-5447
713.659.1336


Affiliates and Resources

Logo Logo Logo Logo Logo


Button